Cardinal Health, Inc. with ticker code (CAH) have now 14 confirmed analysts covering the stock with the consensus suggesting a rating of ‘Hold’. The range between the high target price and low target price is between 97 and 76 and has a mean target at $85.21. Now with the previous closing price of $80.72 and the analysts are correct then we can expect a percentage increase in value of 5.6%. The 50 day MA is $75.61 and the 200 day MA is $71.70. The total market capitalization for the company now stands at $20,773m. Visit the company website at: https://www.cardinalhealth.com
The potential market cap would be $21,929m based on the market consensus.
Cardinal Health, Inc. operates as an integrated healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. It provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home. The company operates in two segments, Pharmaceutical and Medical. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products. The segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; repackages generic pharmaceuticals and over-the-counter healthcare products; and offers medication therapy management and patient outcomes services to hospitals, other healthcare providers, and payers, as well as provides pharmacy management services to hospitals. The Medical segment manufactures, sources, and distributes Cardinal Health branded medical, surgical, and laboratory products and devices that include exam and surgical gloves; needles, syringe, and sharps disposals; compressions; incontinences; nutritional delivery products; wound care products; single-use surgical drapes, gowns, and apparels; fluid suction and collection systems; urology products; operating room supply products; and electrode product lines. The segment also distributes a range of national brand products, including medical, surgical, and laboratory products; provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare providers; and assembles and sells sterile, and non-sterile procedure kits. The company was incorporated in 1979 and is headquartered in Dublin, Ohio.
The company has a dividend yield of 2.46% with the ex dividend date set at 31-3-2023 (DMY).
